While small-cap stocks were lower during a difficult March for the market, Oppenheimer thinks some of these stocks could soar as spring begins. In a note on Wednesday, the firm listed 30 small- and mid-cap stocks that it believes are outperforming and poised for strong upside. Additionally, all stocks have market capitalizations between $1 billion and $12 billion. Of these 30 stocks, Oppenheimer highlighted several that he considers to be the “best of the best.” The best-rated company is Armis, which has had the best year-to-date performance among the companies on the list and has already more than doubled in 2026. The company has a price target of $55, indicating a potential upside of nearly 150% from Tuesday’s closing price. The company’s recent successful trial of its plaque psoriasis drug embuducitinib adds to Oppenheimer analyst Geoff Jones’ bullish stance. “We believe it is very encouraging that envu has demonstrated biologic-like efficacy in this pivotal trial, along with a safety profile that shows no signs of precluding adoption of Bristol-Myers Squibb’s first-generation drug, Ducla.” Nurix Therapeutics also ranks in the “Best of the Best” category. The stock has fallen about 18% since the beginning of the year, but analyst Matthew Biegler has a price target of $28, which would represent an 80% upside from Tuesday’s closing price. Biegler’s positive outlook stems from the company’s portfolio of cancer and autoimmune disease treatments. Finally, cloud platform company DigitalOcean also made the list. Analyst Param Singh has a price target of $100, which would represent an increase of more than 16% from Tuesday’s closing price. “We view DigitalOcean as a turnaround story in the early stages of a multi-year expansion,” Singh wrote. “The company is already showing increased traction and momentum with existing and new customers, and we see customers increasing their use of DigitalOcean’s Infrastructure-as-a-Service and Platform-as-a-Service cloud offerings for artificial intelligence inference workloads.”
